Loading...
•
Mar 31, 2022
Azenta Q2 2022 Earnings Report
Reported preliminary results for the second quarter, driven by robust customer demand and strong operational execution.
Key Takeaways
Azenta Life Sciences reported preliminary financial results for Q2 2022, showing a 12% increase in revenue from continuing operations compared to the previous year. Revenue reached $146 million, driven by growth in both Life Sciences Products and Services. Diluted EPS from continuing operations was ($0.02) per share, while non-GAAP diluted EPS was $0.12.
Revenue from continuing operations was $146 million, a 12% increase year-over-year and a 4% sequential increase.
Life Sciences Products revenue grew 2% year-over-year, driven by automated cryogenic freezers.
Life Sciences Services revenue increased 19% year-over-year, with growth in Sample Repository Solutions and Genomics Services.
Diluted EPS from continuing operations was ($0.02) per share, while total diluted EPS was $28.15, including discontinued operations.
Forward Guidance
The Company announced revenue and earnings guidance for continuing operations for the third quarter of fiscal 2022. Revenue is expected to be in the range of $140 million to $150 million and non-GAAP diluted earnings per share for the third fiscal quarter is expected to be in the range of $0.09 to $0.17. GAAP diluted earnings per share from continuing operations is expected to be in the range of ($0.03) to $0.05.
Positive Outlook
- Revenue is expected to be in the range of $140 million to $150 million.
- Non-GAAP diluted earnings per share for the third fiscal quarter is expected to be in the range of $0.09 to $0.17.
Challenges Ahead
- GAAP diluted earnings per share from continuing operations is expected to be in the range of ($0.03) to $0.05.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...